Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit

NCT06672653 is registered in ClinicalTrials.gov with MGB Pharma as lead sponsor.

NCT NCT06672653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06672653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit
Lead sponsor
MGB Pharma
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 15, 2024
Completion date
July 15, 2025
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

c14, cervical cancers, hiv, hpv infections, hpv-induced cancers, monoterpenoid zinc tetra-ascorbo-camphorate, trial